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Introduction: The objective of this pilot randomized controlled trial was to investigate the 
combined effect of a Mediterranean diet and naltrexone/bupropion treatment on body weight, 
metabolic parameters, and quality of life in overweight or obese breast cancer survivors.
Methods: Forty-four breast cancer survivors were randomly assigned to receive the 
Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet 
+NB group) or the Mediterranean diet alone (breast cancer survivor MeDiet-only group). 
Twenty-eight age-matched non-cancer patients were instructed to consume the 
Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group). 
After the 8-week intervention, changes in body weight, metabolic parameters, nutrient 
intake, and quality of life of the three groups were assessed.
Results: Significant weight loss of 2.8 kg was noted for the breast cancer survivor MeDiet 
+NB group, 1.8 kg for the breast cancer survivor MeDiet-only group, and 2.5 kg for the non- 
cancer MeDiet+NB group after 8 weeks (P < 0.05 versus baseline by Wilcoxon’s signed-rank 
test). All three groups also exhibited significantly lower fasting glucose, insulin, and home-
ostasis model assessment of insulin resistance levels (P < 0.05). Quality of life as assessed by 
self-reported questionnaires showed improvement in all participants (P < 0.05). However, 
there were no significant differences of changes in body weights, metabolic parameters, and 
quality of life among the three groups or between the MeDiet+NB and MeDiet-only groups.
Conclusion: We found that the Mediterranean diet, with or without naltrexone/bupropion 
treatment, facilitates weight loss, improves metabolic parameters, and increases quality of 
life. The combination of the Mediterranean diet with naltrexone/bupropion treatment did not 
produce superior changes when compared to the Mediterranean diet alone.
Trial Registration: This trial was retrospectively registered on 10 July 2018 as 
NCT03581630 at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03581630).
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Introduction
Breast cancer is a leading cause of cancer among women worldwide and the second most 
common cancer among women in Korea. From 1993 to 2015, the 5-year survival rate for 
breast cancer patients increased from 78.0% to 92.3% in Korea,1 indicating the increased 
importance of health care for survivors. Overweight or obesity is associated with a higher 
risk for cancer recurrence and mortality among breast cancer survivors.2,3 Furthermore, 
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obesity is associated with psychosocial problems, a low qual-
ity of life, and increased metabolic risk factors.4,5 Thus, the 
American Cancer Society and the American Society of 
Clinical Oncology recommend that cancer survivors achieve 
and maintain a healthy weight.6 Recent studies have begun 
examining the effect of weight loss intervention in overweight 
or obese breast cancer survivors.7,8 However, the bulk of these 
studies were conducted only in Western countries, and few 
have been conducted in Asian countries.
Weight loss intervention to address overweight or obesity 
should include comprehensive lifestyle modifications, and 
drug treatment for obesity is recommended as an adjunctive 
therapy.9 The Mediterranean diet, recently known as an 
effective alternative to low-fat or low-carbohydrate diets in 
terms of weight loss, is associated with a significant reduc-
tion in cardiovascular disease and total mortality, as well as 
body weight.10,11 Moreover, an updated meta-analysis pool-
ing seven cohort studies reported an inverse association 
between the incidence of breast cancer and adherence to 
a Mediterranean diet.12 In a secondary analysis of the 
PREDIMED (Prevención con Dieta Mediterránea) clinical 
trial, individuals consuming a Mediterranean diet supple-
mented with extra-virgin olive oil had a reduced incidence 
of breast cancer.13 These findings suggest that the 
Mediterranean diet would be an effective dietary intervention 
for overweight or obese breast cancer survivors.
With regard to pharmacological therapies to improve 
weight loss, the combination of the opioid receptor antagonist 
naltrexone and the norepinephrine-dopamine reuptake inhibi-
tor bupropion (Contrave; Orexigen, La Jolla, CA, USA) was 
recently approved and shows long-term safety and efficacy. 
Bupropion’s anorectic effect is the result of the stimulation of 
hypothalamic pro-opiomelanocortin neurons, whereas naltrex-
one blocks opioid-mediated autoinhibition of these cells.14 In 
addition, low-dose naltrexone inhibits tumor progression by 
upregulating the expression of opioid growth factor and its 
receptor.15,16 Furthermore, bupropion has been shown to 
improve sexual function in breast cancer patients.17,18 
Therefore, the combination of naltrexone and bupropion may 
be beneficial for not only non-cancer obese people but also 
breast cancer survivors.
The aim of our study was to investigate the effect of 
the Mediterranean diet and naltrexone/bupropion treatment 
on body weight, metabolic parameters, and quality of life 
in breast cancer survivors who are overweight or obese. 
We also evaluated whether obesity drugs have an addi-
tional effect compared to the Mediterranean diet alone and 
whether there are any differences in breast cancer survi-
vors, compared to non-cancer obese people.
Methods
Study Design
This 8-week, three-arm parallel-group, randomized con-
trolled trial was conducted at Gangnam Severance Hospital 
(Seoul, South Korea) from July 2017 to July 2018. The study 
design and experimental protocol were approved by the 
Institutional Review Board of Gangnam Severance 
Hospital (IRB number 3–2017-0097) in accordance with 
the Declaration of Helsinki. Written informed consent was 
obtained from each participant before screening and data 
collection. This trial was retrospectively registered at 
ClinicalTrials.gov (number NCT03581630).
Study Participants
Breast cancer survivors and age-matched non-cancer 
patients were recruited via poster and online advertise-
ments at Gangnam Severance Hospital. All volunteers 
were initially screened by telephone. Women aged 20–65 
years were eligible for inclusion if they had a body mass 
index (BMI) >25.0 kg/m2 (obese for Asian populations, 
according to the World Health Organization19) or a BMI 
>23.0 kg/m2 (overweight for Asian populations) in the 
presence of at least one metabolic risk factor (waist cir-
cumference ≥80 cm, triglyceride ≥150 mg/dL, high- 
density lipoprotein [HDL] cholesterol <50 mg/dL, fasting 
glucose ≥100 mg/dL, blood pressure ≥130/85 mmHg, or 
a diagnosis of hypertension, type 2 diabetes mellitus, or 
dyslipidemia currently controlled with medications). 
Participants who were diagnosed with breast cancer stage 
I–III and completed cancer treatment, including surgery, 
adjuvant chemotherapy, radiotherapy, and/or hormonal 
therapy, were included in the breast cancer survivor group.
Participants who met any of the following criteria were 
excluded: uncontrolled hypertension, hepatic or renal disease, 
significant cardiovascular disease or stroke, history of seizures, 
serious psychiatric illness (such as bipolar disorder, schizo-
phrenia, bulimia, anorexia nervosa, or suicidal ideation), tak-
ing medications such as monoamine oxidase inhibitors, 
opioid-containing medications, other naltrexone- or bupro-
pion-containing medications, or tamoxifen, history of alcohol 
abuse or dependence, current smokers or use of nicotine 
replacement products in the previous 6 months, or women 
who were pregnant or breastfeeding. Participants with 
a history of breast cancer were excluded if they had 
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experienced cancer recurrence or metastasis. Women of child-
bearing age were required to use effective contraception 
throughout the study period and up to 30 days after disconti-
nuation of the study drug.
Randomization
Breast cancer survivors were randomly assigned to receive 
the Mediterranean diet plus naltrexone/bupropion medica-
tion (MeDiet+NB group) or the Mediterranean diet alone 
(MeDiet-only group). Participants were randomized using 
a computer-generated random number sequence with 
a block size of four. An independent statistician generated 
the allocation sequence, and the study coordinator 
assigned the participants to interventions in chronological 
order as the participants enrolled. Only outcome assessors 
were blinded to group allocation.
Intervention
Mediterranean Diet
All participants participated in the Mediterranean diet inter-
vention and received dietary training from professional nutri-
tionists at the baseline visit and samples of a Mediterranean 
diet for three times during the trial. To assess adherence to the 
Mediterranean diet, a 13-item questionnaire developed by the 
PREDIMED study group that modified the validated 
Mediterranean Diet Adherence Screener was used.20 
However, given the study population and evidence linking 
alcohol consumption with cancer,21 the item for wine con-
sumption was excluded. The resulting modified scores ran-
ged from 0 to 13, with scores higher than 9 defined as high 
adherence to the Mediterranean diet. Participants were edu-
cated to increase the scores by the following diet modifica-
tions: (i) abundant use of olive oil, sesame oil, or perilla oil 
for cooking and dressing; (ii) increased consumption of 
vegetables, fresh fruits, legumes, fish, nuts, white meat, and 
sauce made with tomato, onion, garlic, or olive oil; and (iii) 
avoidance of red or processed meat, butter or cream, sugar- 
sweetened beverages, and commercial sweets or pastries. 
Details of the modified Mediterranean diet score question-
naire are provided in the online supporting material (Table 
S1). Total calorie restriction of <1500 kcal per day was 
advised, which is a 500 kcal deficit from the daily recom-
mended calories calculated according to the method pre-
sented by the Korean Diabetes Association.22 All 
participants were encouraged to communicate with the 
study researchers via mobile messenger by submitting their 
daily diet photographs and Mediterranean diet scores and 
receiving feedback (Figure S1).
Naltrexone/Bupropion Medication
Breast cancer survivors assigned to the MeDiet+NB group and 
all non-cancer patients were instructed to take naltrexone/ 
bupropion. Participants took one extended-release tablet con-
taining 8 mg naltrexone and 90 mg bupropion each morning 
for the first week. Then if tolerable, they increased the daily 
dose to two tablets, one in the morning and one in the evening 
for the next 7 weeks. Drug compliance was measured by the 
remaining pill count at week 1, 4, and 8. Noncompliant parti-
cipants (compliance rate of less than 80%) were discontinued 
from the study.
Outcome Measurements
Body weight (nearest 0.1 kg) of participants, wearing light- 
weight clothing, was measured along with their height (nearest 
0.1 cm) by using an automatic extensometer (BSM 330; 
Biospace, Seoul, South Korea). BMI was calculated as the 
ratio of weight (kg) to height squared (m2). To assess body 
composition, skeletal muscle mass, fat mass, and fat percen-
tage were measured using a bioelectrical impedance analyzer 
(ACCUNIQ BC720; SELVAS Healthcare Inc., Daejeon, South 
Korea). Waist circumference was measured at the horizontal 
plane midway between the lowest ribs and the iliac crest with 
the participant in a standing position.
Fasting blood samples were collected from an antecubital 
vein to assess metabolic parameters at baseline and after the 
8-week intervention. White blood cell (WBC) counts were 
quantified with an XN-9000 hematology analyzer (Sysmex, 
IL, USA). Fasting glucose, high-sensitivity C-reactive protein, 
total cholesterol, triglyceride, and HDL cholesterol levels were 
measured with the ADVIA 1650 Clinical Chemistry system 
(Siemens Medical Solutions, Tarrytown, NY, USA). Unless 
triglycerides were >400 mg/dL, low-density lipoprotein (LDL) 
cholesterol levels were calculated using the Friedewald equa-
tion as follows: LDL cholesterol = total cholesterol − HDL 
cholesterol – triglyceride/5.23 Fasting insulin was measured by 
an electrochemiluminescence immunoassay using an Elecsys 
2010 instrument (Roche, Indianapolis, IN, USA). Insulin resis-
tance was estimated using the homeostasis model assessment 
of insulin resistance (HOMA-IR) method by applying the 
following formula: HOMA-IR = fasting insulin (μIU/mL) × 
fasting glucose (mg/dL)/405.24
At baseline and after the intervention, participants com-
pleted six questionnaires. The 24-h dietary recall method was 
used to calculate the intake of total calories and specific nutri-
ents. The above-mentioned modified Mediterranean Diet 
Adherence Screener was used to assess adherence to the 
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Mediterranean diet. The Godin Leisure-Time Exercise 
Questionnaire was used to calculate the quantity of physical 
activity in metabolic equivalent-hours per week. Quality of life 
was measured using three common questionnaires: the 
European Organisation for Research and Treatment of 
Cancer quality of life questionnaire (EORTC QLQ-C30), the 
obesity-related problems (OP) scale, and the Functional 
Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) 
subscale. The EORTC QLQ-C30 comprises 30 items, includ-
ing global health status, five functional scales, and eight symp-
tom scales.25 High scores on global health status and five 
functional scales indicate a better quality of life. The OP 
scale primarily focuses on the impact of obesity on psychoso-
cial functioning, and higher scores indicate more problems.26 
The FACIT-F subscale uses 13 items to measure fatigue- 
related difficulty in managing daily activities, with higher 
scores indicating less fatigue and a better quality of life.27
Safety assessments consisted of evaluations of treatment 
emergent adverse events, concomitant medications, vital signs 
(recorded at each visit), and clinical laboratory measures 
(recorded at baseline and at week 8), including serum creati-
nine and liver function tests.
Statistical Analysis
All data are presented as the medians (interquartile ranges). 
Differences in baseline characteristics between the 
intervention groups were analyzed on the intention-to-treat 
population using the Kruskal–Wallis test. The primary and 
secondary endpoints were analyzed on the per-protocol popu-
lation. Within-group differences after the intervention were 
analyzed by the Wilcoxon’s signed-rank test, and differences 
between groups postintervention were analyzed using the 
Quade’s rank analysis of covariates, adjusted for age and initial 
BMI. A P value of < 0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS for Windows 
(version 23.0; SPSS Inc., Chicago, Ill., USA). The datasets 
used and/or analyzed during the present study are available 
from the corresponding author on reasonable request.
Results
Baseline Characteristics
A total of 75 candidates were screened for eligibility, and 72 
participants (44 breast cancer survivors and 28 non-cancer 
patients) were enrolled in the study. The rate of study discon-
tinuation was 22.2% (MeDiet+NB, 29.4%; MeDiet-only, 
4.8%). In total, 56 participants finally completed the study 
(Figure 1). The baseline characteristics of participants are 
shown in Table 1. We found no significant differences between 
the groups with regard to age, body weight, or metabolic 
parameters at baseline. However, BMIs differed at baseline 
Figure 1 Flow chart of study participant selection.
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between the groups; therefore, we analyzed the outcomes after 
adjusting for initial BMI.
Adherence to the Dietary Intervention
After the 8-week intervention, the percentages of participants 
with high adherence to the Mediterranean diet (score of ≥9) 
increased in all three groups (Figure 2). Changes in nutrient 
intake measured by 24-h dietary recall method are listed in 
Table 2. Monounsaturated fatty acid/saturated fatty acid ratio 
and dietary fiber intake increased after 8 weeks (P = 0.046 
and P < 0.001, respectively), and the median total calorie 
intake decreased to <1500 kcal per day, which reflects high 
adherence to the Mediterranean diet. The comparison of 
changes in nutrient intake among the study groups revealed 
no significant differences, since the same dietary intervention 
was advised to all three groups (Online supplementary Table 
S2). In addition, physical activity increased after 8 weeks in 
all participants (P < 0.001) (Table 2), although the changes 
did not differ among groups (Table S2).
Endpoints
Table 3 shows the changes in body weight, body composition, 
and metabolic parameters after the intervention. Body weight, 
BMI, and fat mass decreased in all three groups after 8 weeks 
(P < 0.05 versus baseline by Wilcoxon’s signed-rank test). 
Quade’s rank analysis of covariates, adjusted for age and initial 
BMI, was performed to estimate the statistical differences 
between groups. However, there were no significant differ-
ences among the three groups or between the MeDiet+NB and 
MeDiet-only groups.
Table 1 Baseline Characteristics of the Study Participants
Characteristics Breast Cancer Survivors Non-Cancer Patients P valuea
MeDiet+NB MeDiet Only MeDiet+NB
(n = 23) (n = 21) (n = 28)
Age (years) 56.0 (52.0, 57.5) 55.0 (50.5, 58.8) 53.5 (49.5, 57.0) 0.329
Body composition
Weight (kg) 66.7 (63.1, 71.1) 65.7 (61.7, 69.1) 72.0 (64.5, 80.1) 0.076
BMI (kg/m2) 27.6 (25.7, 28.6) 26.2 (24.9, 27.4) 29.2 (25.7, 31.4) 0.025
Skeletal muscle (kg) 22.7 (21.1, 23.9) 22.0 (21.4, 22.8) 23.1 (21.1, 25.9) 0.459
Fat mass (kg) 24.8 (22.9, 28.5) 23.6 (21.0, 28.6) 29.1 (23.3, 32.3) 0.083
Fat percentage 37.1 (36.3, 41.2) 37.1 (34.7, 42.4) 38.7 (35.2, 43.5) 0.329
WHR 0.91 (0.90, 1.00) 0.91 (0.87, 0.98) 0.92 (0.88, 1.00) 0.604
Diet and physical activity
Total calorie (kcal/day) 1744.8 (1188.7, 2068.0) 1653.8 (1321.6, 1883.4) 1449.8 (1295.2, 1999.8) 0.901
Mediterranean diet score 8.0 (5.5, 10.0) 8.0 (7.0, 9.8) 7.0 (4.5, 9.0) 0.259
GLTEQ score (MET-h/wk) 9.0 (0.0, 26.5) 6.0 (3.0, 14.5) 4.8 (0.0, 17.5) 0.642
Metabolic parameters
WBC count (no./μL) 5.55 (4.93, 6.19) 5.15 (4.40, 5.78) 5.25 (4.46, 6.26) 0.597
Fasting glucose (mg/dL) 88.0 (82.5, 105.5) 85.5 (79.0, 97.5) 86.0 (82.0, 97.5) 0.643
Insulin (μIU/mL) 7.50 (5.15, 12.00) 7.45 (5.33, 9.58) 7.90 (5.05, 9.80) 0.880
HOMA-IR 1.52 (1.08, 2.78) 1.49 (1.19, 2.25) 1.70 (1.06, 2.51) 0.804
Total cholesterol (mg/dL) 196.0 (153.5, 209.5) 196.5 (182.3, 219.0) 193.0 (165.5, 207.5) 0.478
Triglyceride (mg/dL) 136.0 (121.0, 186.5) 124.0 (92.5, 193.5) 112.0 (87.0, 145.5) 0.140
HDL cholesterol (mg/dL) 56.6 (49.8, 59.5) 54.0 (47.5, 64.1) 64.0 (47.7, 71.7) 0.262
LDL cholesterol (mg/dL) 109.9 (63.5, 130.1) 113.5 (99.0, 132.7) 110.1 (84.8, 124.3) 0.537
Vital signs
Systolic BP (mmHg) 121.0 (117.5, 125.5) 127.5 (119.8, 140.8) 123.0 (116.5, 133.5) 0.173
Diastolic BP (mmHg) 79.0 (77.5, 84.0) 87.0 (77.3, 97.3) 79.0 (74.0, 85.0) 0.143
Heart rate (beats/min) 72.0 (66.5, 83.5) 75.0 (68.3, 80.8) 75.0 (67.0, 84.0) 0.812
Notes: Data are expressed as medians (interquartile ranges). aP values calculated by the Kruskal–Wallis test. 
Abbreviations: BMI, body mass index; BP, blood pressure; GLTEQ, Godin Leisure-Time Exercise Questionnaire; HDL, high-density lipoprotein; HOMA-IR, homeostasis 
model of assessment-insulin resistance; LDL, low-density lipoprotein; MeDiet, Mediterranean diet; MET-h/wk, metabolic equivalents-hour/week; NB, naltrexone/bupropion; 
WBC, white blood cell; WHR, waist-hip ratio.
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Among measures of metabolic parameters, fasting glu-
cose, insulin, and HOMA-IR significantly decreased in all 
three groups (P < 0.05 versus baseline by Wilcoxon’s 
signed-rank test) (Table 3). In addition, WBC count, total 
cholesterol, triglyceride, and LDL cholesterol were slightly 
reduced in all three groups, some with statistically significant 
within-group changes. Among the groups, only triglyceride 
levels were significantly different (P = 0.025 by Quade’s 
rank analysis of covariates). Other metabolic parameters 
were not significantly different among the three groups or 
between the MeDiet+NB and MeDiet-only groups.
In all participants, quality of life as assessed by self- 
reported questionnaires improved after the intervention 
(Figure 3). Global health status and five functional scales, as 
assessed by the EORTC QLQ-C30, significantly increased 
after 8 weeks (P < 0.05 by Wilcoxon’s signed-rank test). The 
FACIT-F subscale also increased (P = 0.002) and OP scale 
decreased (P = 0.031), indicating quality of life improvements. 
No significant differences in quality of life were found among 
the groups (Online supplementary Table S3).
Safety and Tolerability
Vital signs, including blood pressure and heart rate, were in the 
normal or prehypertension range at baseline in all three groups 
(Table 1). After 8 weeks, systolic blood pressure significantly 
decreased in the cancer survivor MeDiet-only group and the 
non-cancer MeDiet+NB group (P < 0.05 by Wilcoxon’s 
signed-rank test, data not shown). Diastolic blood pressure 
significantly decreased only in the non-cancer patient group, 
and heart rate showed no significant change in all three groups. 
Clinical laboratory measures, including serum creatinine and 
liver function tests, showed no evidence of treatment-related 
hepatotoxicity or nephrotoxicity (data not shown).
Figure 2 Percentages of participants with a Mediterranean diet score (MDS) ≥9 by group.
Table 2 Changes in Nutrient Intake and Physical Activity After 
Intervention








Carbohydrate (%) 54.5 (42.8, 62.3) 54.6 (47.5, 60.9) 0.519
Protein (%) 15.9 (14.2, 17.7) 15.9 (13.9, 20.2) 0.405
Total fat (%) 28.3 (22.4, 34.7) 28.4 (24.1, 35.2) 0.807
SFA (%) 5.2 (3.2, 7.2) 5.7 (4.0, 7.2) 0.967
MUFA (%) 6.5 (4.8, 9.1) 8.3 (5.6, 10.5) 0.267
PUFA (%) 8.2 (4.8, 10.7) 9.0 (4.8, 13.4) 0.332
n-3 PUFA (%) 0.43 (0.05, 0.84) 0.57 (0.12, 1.31) 0.209
n-6 PUFA (%) 2.39 (0.65, 5.13) 3.17 (0.79, 6.67) 0.212
MUFA/SFA ratio 1.24 (1.09, 1.51) 1.35 (1.13, 1.84) 0.046
PUFA/SFA ratio 1.75 (0.90, 2.45) 1.64 (1.02, 2.28) 0.832
Dietary fiber (g/ 
1000 kcal)
13.5 (8.8, 17.9) 18.2 (11.9, 23.3) <0.001
GLTEQ score 7.1 (2.0, 18.0) 15.8 (4.7, 30.0) <0.001
Notes: Data are expressed as medians (interquartile ranges). aP values calculated 
by Wilcoxon’s signed-rank test. 
Abbreviations: MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty 
acid; SFA, saturated fatty acid; GLTEQ, Godin Leisure-Time Exercise Questionnaire.
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Of the 51 participants who received the naltrexone and 
bupropion treatment, 39 participants (76%) experienced 
adverse effects during the trial. Nausea was the most 
frequent adverse effect (39%), followed by dizziness 
(33%), dry mouth (25%), and constipation (22%). The 
symptoms were mostly mild to moderate in intensity. 
One serious adverse effect, syncope, occurred in the non- 
cancer patient group, which was considered unlikely 
related to the study drug. Nine participants discontinued 
the study due to adverse effects, including nausea (10%), 
urticaria (4%), dizziness (2%), and syncope (2%).
Discussion
This study is the first to report the combined effect of 
a Mediterranean diet and naltrexone/bupropion treatment 
on body weight, metabolic parameters, and quality of life 
in breast cancer survivors who are overweight or obese, 
known risk factors for cancer recurrence and mortality. 
The 8-week interventions reduced body weights, BMI, 
and fat mass, while improving metabolic parameters and 
quality of life in all participants. However, no significant 
difference among the three groups was observed.
Unexpectedly, we found no additional effect of naltrexone/ 
bupropion medication on body weight and metabolic para-
meters despite evidence from previous studies showing effec-
tive weight reduction with these drugs.28,29 This discrepancy 
may be due to the low dose of naltrexone/bupropion used in 
this study. Unlike previous studies using the approved max-
imum doses of naltrexone (32 mg) and bupropion (360 mg), 
only half of the doses were used in this study. The open-label 
aspect of the study without a placebo could also be a reason. 
An increase in physical activity was seen in the MeDiet-only 
group, which could suggest that the participants in this group 
made more efforts to achieve lifestyle modifications because 
they did not take the obesity drugs.
Although this pilot study could not accurately evalu-
ate the effectiveness of the Mediterranean diet since 
there was no control group without the Mediterranean 
diet, our results are consistent with previous randomized 
clinical trials demonstrating the benefits of the 
Mediterranean diet for body weight and metabolic 
parameters.30,31 The PREDIMED study group reported 
reduced fasting glucose, insulin, and insulin resistance as 
short-term effects on cardiovascular risk factors of the 
Mediterranean diet, compared to a low-fat diet,32 which 
is in agreement with findings obtained in our study. 
Monounsaturated fats from olive oil, an important com-
ponent of the Mediterranean diet, have been shown to 
help improve glucose metabolism and insulin sensitivity, 
as well as increase postprandial fat oxidation.33,34 The 
effects of the Mediterranean diet on body weight and 
composition are attributed to a low consumption of 
Table 3 Changes in Body Weight, Body Composition, and Metabolic Parameters After Intervention
Parameters Breast Cancer Survivors Non-Cancer Patients P valuea P valueb
MeDiet+NB MeDiet Only MeDiet+NB
(n = 14) (n = 20) (n = 22)
Weight (kg) −2.8 (−3.6, −1.9)* −1.8 (−3.3, −0.6)* −2.5 (−4.2, −1.8)* 0.394 0.209
BMI (kg/m2) −1.1 (−1.5, −0.7)* −0.7 (−1.4, −0.2)* −1.0 (−1.7, −0.7)* 0.404 0.212
Skeletal muscle (kg) −0.1 (−0.8, 0.3) −0.4 (−0.8, 0.6) −0.2 (−1.2, 0.1)* 0.938 0.867
Fat mass (kg) −1.7 (−3.2, −0.8)* −1.8 (−2.7, −0.6)* −2.3 (−3.0, −0.1)* 0.771 0.469
Fat percentage (%) −1.4 (−3.6, 0.3)* −1.4 (−2.7, 1.1) −1.6 (−2.9, −0.4)* 0.623 0.393
WHR −0.02 (−0.05, 0.01)* −0.01 (−0.04, 0.02) −0.01 (−0.04, −0.01)* 0.386 0.169
WBC count (no./μL) −0.01 (−0.69, 0.78) −0.66 (−0.94, 0.10)* −0.01 (−0.74, 1.06) 0.503 0.241
Fasting glucose (mg/dL) −10.0 (−18.5, −6.0)* −7.0 (−13.0, −3.0)* −12.0 (−15.0, −6.5)* 0.627 0.332
Insulin (μIU/mL) −2.60 (−4.15, 0.25)* −1.10 (−2.10, −0.10)* −1.70 (−2.85, −0.05)* 0.467 0.455
HOMA-IR −0.65 (−1.09, −0.13)* −0.40 (−0.50, −0.17)* −0.41 (−0.99, −0.14)* 0.589 0.595
Total cholesterol (mg/dL) −23.0 (−32.5, −0.5)* −5.0 (−23.0, 7.0) −18.0 (−24.0, 3.5)* 0.461 0.245
Triglyceride (mg/dL) −41.0 (−59.0, −23.0)* −25.0 (−57.0, 8.0)* −4.0 (−26.0, 28.0) 0.025 0.703
HDL cholesterol (mg/dL) 0.4 (−1.2, 6.2) 0.4 (−2.2, 7.8) −0.7 (−5.0, 8.6) 0.735 0.763
LDL cholesterol (mg/dL) −16.6 (−24.9, 5.2) −7.7 (−17.6, 9.1) −10.4 (−27.2, −0.2)* 0.274 0.139
Notes: Data are expressed as medians (interquartile ranges). aDifferences among the three groups were calculated by Quade’s rank analysis of covariates, adjusted for age 
and initial BMI. bDifferences between the MeDiet+NB and MeDiet-only groups were calculated by Quade’s rank analysis of covariates, adjusted for age and initial BMI. 
*P value <0.05 vs baseline values by Wilcoxon’s signed-rank test. 
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, homeostasis model of assessment-insulin resistance; LDL, low-density lipoprotein; 
MeDiet, Mediterranean diet; NB, naltrexone/bupropion; WBC, white blood cell; WHR, waist-hip ratio.
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animal products and high consumption of vegetables, 
fruits, and legumes. This diet is not energy dense, has 
a low glycemic load, and has large amounts of vitamins 
and dietary fiber,35 which was confirmed by our data.
In the present study, we also found that there were no 
differences in the results for breast cancer survivors and non- 
cancer obese people: only the dropout rate due to the adverse 
events of the obesity drug was higher in breast cancer survi-
vors. This may be because the breast cancer survivors could 
feel more anxious about adverse events, such as nausea, than 
non-cancer people. To our knowledge, this is the first weight 
loss intervention using obesity drugs in breast cancer survi-
vors, while the benefits of the Mediterranean diet for breast 
cancer patients are relatively well known. Oleic acid in olive 
oil has been shown to regulate oncogenes in human breast 
cancer cells.36 Moreover, oleocanthal, a polyphenol in olive 
oil, has been found to inhibit the proliferation, invasion, and 
growth of tumor cells in vitro and in breast cancer models 
in vivo.37 Therefore, the Mediterranean diet appears to be 
helpful as a dietary intervention in breast cancer patients. 
Further studies about the choice of obesity drugs to breast 
cancer patients are warranted.
The present study has several limitations. First, the use 
of an 8-week intervention precluded investigations of the 
effectiveness of the intervention on weight maintenance or 
cancer recurrence. Second, we recruited non-cancer 
patients matched to survivors by age, not BMI. As 
a result, the baseline BMIs differed between groups, 
requiring adjustments for this factor in statistical analyses. 
Third, we relied on self-reported dietary intake using the 
Figure 3 Changes in quality of life as assessed by questionnaires. (A) Global health status (QL) and five functional scales, namely, physical functioning (PF), role functioning 
(RF), emotional functioning (EF), cognitive functioning (CF), and social functioning (SF), of EORTC QLQ-C30 at baseline and week 8. (B) FACIT-F subscale at baseline and 
week 8. (C) OP scale at baseline and week 8.
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24-h dietary recall method, which may have recall bias. 
However, the increased monounsaturated fatty acid/satu-
rated fatty acid ratio and dietary fiber measurements by 
24-h dietary recall method were consistent with consump-
tion of a Mediterranean diet. Finally, the rate of study 
discontinuation was higher than the anticipated dropout 
rate of 10%. Most of the participants reported dropping 
out due to the adverse effects of the naltrexone/bupropion 
medication.
Conclusions
In summary, we found that the Mediterranean diet, with or 
without naltrexone/bupropion treatment, facilitates weight 
loss, improves metabolic parameters, and increases quality 
of life in breast cancer survivors who are overweight or 
obese. The combination of the Mediterranean diet with 
naltrexone/bupropion treatment did not produce superior 
changes in outcomes when compared to the Mediterranean 
diet alone. Future studies should include a larger number 
of participants over a longer period of time to determine 
the effect of the Mediterranean diet on breast cancer recur-
rence or survival.
Abbreviations
BMI, body mass index; EORTC QLQ-C30, European 
Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire; FACIT-F, Functional 
Assessment of Chronic Illness Therapy-Fatigue; HDL, 
high-density lipoprotein; HOMA-IR, homeostasis model 
assessment of insulin resistance; LDL, low-density lipo-
protein; MeDiet, Mediterranean diet; NB, naltrexone/ 
bupropion; OP, obesity-related problems; PREDIMED, 
Prevención con Dieta Mediterránea; WBC, white blood 
cell.
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